Shares in Cizzle Biotechnology Holdings PLC (LSE:CIZ) were up 5% following the announcement of a significant expansion in its research agreement with the University of York.
This collaboration is centred on the CIZ1B biomarker technology, aimed at early-stage cancer diagnosis and potential cancer therapies.
The company has achieved major milestones, including the successful isolation of new monoclonal antibodies specific to the CIZ1B biomarker. These have been incorporated into an innovative high-throughput clinical diagnostic immunoassay platform.
With these advancements, Cizzle is gearing up for commercial clinical trials, aiming to validate and accredit the CIZ1B test before its market launch.
Originating from the University of York in 2006, the company retains all intellectual property rights from this research, further bolstering its position in the market.
The stock was up 0.1p at 2.2p.